secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066930
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.
- Net loss $18.8M ($0.17 loss per share) vs $2.1M loss in Q1 2024; adjusted EBITDA loss $12.5M vs income $2.6M.
- Cash $110.5M, no debt; cash used in operations $19.9M vs $10.2M in prior year.
- FY2025 revenue guidance reaffirmed at $480M-$535M; updated net income guidance $4.7M-$34.0M (from prior range).
- ReNu BLA submission on track for end of 2025; second phase 3 study patient enrollment expected by end of Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/0000950170-25-066930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/orgo-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer